Theodore Stewart Gourdin

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma”.

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-005813

N/A

0.810DataRank · unranked

25 citations

Jean‐Laurent Deville, Mario Sznol, Alain Ravaud, Marco Maruzzo, Russell K. Pachynski +14 more

Prognostic implications of gene amplifications identified by circulating tumor DNA (ctDNA) analysis in metastatic prostate cancer (mPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e17594

N/A

0DataRank · unranked

0 citations

Antonio Giordano, Hong Li, Theodore Stewart Gourdin, Leylah Drusbosky, Philip H. Howe +2 more

Phase II trial of opaganib in patients with metastatic castration-resistant prostate cancer progressing on abiraterone or enzalutamide (NCT04207255).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.tps191

N/A

0DataRank · unranked

3 citations

Charles D. Smith, Terry F. Plasse, Besim Öğretmen, Shikhar Mehrotra, Theodore Stewart Gourdin +6 more

Genomic amplifications identified by circulating tumor DNA analysis guide prognosis in metastatic castration-resistant prostate cancer

Frontiers in Oncology(2024)10.3389/fonc.2023.1202277

N/A

0DataRank · unranked

2 citations

Joseph A. Karam, Antonio Giordano, Hong Li, Leylah Drusbosky, Theodore Stewart Gourdin +3 more

Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma

The Oncologist(2025)10.1093/oncolo/oyaf138

N/A

0DataRank · unranked

0 citations

Neil J. Shah, Matthew T. Campbell, Naomi B. Haas, Ariel Ann Nelson, Moshe Chaim Ornstein +12 more